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Abstract
Treatment of acute myeloid leukemia (AML) extramedullary relapse (EMR) 
after allogenic hematopoietic stem cell transplantation (alloHSCT) is challenging. 
EMR pathogenesis of this entity is not clearly elucidated. Variety of factors affect 
clinical approaches in diagnostics, treatment and prognosis. Furthermore, there 
is no current consensus for post-transplant AML EMR treatment. We present 
here the case of young AML female patient with rare EMR presentation: ovary 
and large intestine infiltration. The treatment combined different strategies – 
conservative like surgery and chemotherapy, but also effective new approaches 
of targeted therapy - hypomethylating agent with tyrosine kinase inhibitor. 
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Abbreviations 
AML: Acute Myeloid Leukemia; BAL: Bronchoalveolar Lavage 
; CBF: Core Binding Factor; FAM: Fluticasone/Azitromycine/
Montelukast; FDG: Fluorodeoxyglucose; HRCT: High Resolution 
Computed Tomography; MIP: Maximum Intensity Projection; 
MRD: Minimal Residual Disease; PET/CT: Positron Emission 
Tomography/Computed Tomography; SIRS: Systemic Inflammatory 
Response Syndrome; SUVmax: Maximal Standardized Uptake Value; 
TK: Tyrosine Kinase 
Case Presentation 
23-year-old female patient was diagnosed with acute myeloid 
leukemia (AML) inv16 (CBF-MYH11) with c-KIT mutation in July 
2011. The patient underwent induction chemotherapy according 
to the DAC-7 protocol (Daunorubicin 60 mg/m^2/day i.v., days 
1–3; Cytarabine 200 mg/m^2/day, days 1-7; Cladribine 5 mg/m^2/
day, days 1-5) and complete hematological remission was achieved. 
Consolidation consisted of 2 cycles with high dose Cytarabine (HAM: 
Cytarabine 1.5 g/m^2/day i.v. D: 1-3; Mitoxantrone 10 mg/m2 D: 3-5 
in September 2011 and HD-Ara-C: Cytarabine 2 g/m^2 i.v. D 1, 3, 
5 in October 2011). Aplasia period, after second consolidation, was 
complicated by severe diarrhea with Clostridium difficile etiology. 
Molecular MRD was positive after induction and consolidation 
and the patient was qualified for matched related donor allogeneic 
hematopoietic stem cell transplantation (MRD alloHSCT). In January 
2013, the patient was admitted to transplant unit and subjected to 
10/10 MRD peripheral blood stem cells transplantation with reduced 
toxicity conditioning according to BuClo regimen (Busilvex 3.2 
mg/kg/day i.v. D-5 to -2 and Clofarabine 30mg/m^2/day i.v. D-6 
to -2). Hematological recovery was achieved (WBC>1,5×10^9/l on 
D+18, ANC>0.5×10^9/l on D+18, PLT>20×10^9/l on D+10, PLT 
>50×10^9/l on D+10). First chimerism analysis revealed complete 
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donor chimerism, but molecular minimal residual disease (MRD) 
signal - CBF-MYH11 was positive. Because of high risk of relapse 
immunosupression was tapered and finally discontinued on D+120. 
In September 2012, 6 months after transplant, the patient developed 
dry cough and dyspnoea at exertion. Spirometry revealed severe 
obturation, there were no abnormalities in HRCT assessment. 
Bronchiolitis obliterates syndrome was diagnosed and the patient 
restarted systemic immunosuppression (Tacrolimus+steroids) 
collaterally with FAM (inhaled Fluticasone/Azithromycin/
Montelukast) and Posaconazole prophylaxis with good response. In 
March 2013 after respiratory tract infection the patient complained 
of prolonged productive cough and malaise. HRCT results and 
microbiological BAL culture (Aspergillus fumigatus) confirmed 
invasive pulmonary aspergillosis. Voriconazole treatment led to 
resolution of symptoms and typical abnormalities in imaging. In 
regular control of the asymptomatic patient in September 2015, 44 
months after transplantation, molecular analysis revealed positive 
CBF-MYH11. With no abnormalities found both in CBC and bone 
marrow assessment, positron emission tomography (PET/CT) was 
performed and presented increased FDG metabolism in the region 
of left ovary. Surgically removed left ovary was enlarged 50x70 mm, 
hard, motionless with ovarian cavity and lateral wall of the uterus. 
In histopathology, ovary was massively infiltrated by atypical cells 
with morphology of blasts. In subsequent peripheral blood MRD 
molecular analysis was still positive and PET/CT revealed increased 
FDG metabolism in the left side of lower intestine. The patient was 
subjected to colonoscopy with biopsy. There was no pathology 
on inspection and in histopathology nonspecific scanty lymphoid 
infiltrates were found. 2-month later, next PET/CT was performed 
and metabolically active areas of the descending colon 52x44x47 
mm, SUVmax 7.2; on the border of descending colon and distal 
segment 29x32x36 mm SUVmax 6.2 and intestinal loops, right from 
the rectum 55x53x46mm SUVmax 8.8 were noted (Figure1A,1B). 
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Second colonoscopy confirmed diagnosis of extramedullary AML 
relapse in large intestine. To minimize the risk of severe bleeding and 
perforation, therapy was started with Dasatinib 100 mg/day orally 
with 5-Azacytidine 75 mg/m^2 for 7 days used off-label followed 
by systemic chemotherapy: Cytarabine 200 mg/m^2/day (1-5) + 
Idarubicine 12 mg/m^2/day (1-3) and 90%-regression of infiltrate 
was achieved, confirmed by PET/CT with negative molecular MRD. 
Double induction was planned, and the patient was subjected to 2nd 
course - Cytarabine 200mg/m^2/day (1-5) + Idarubicine 12mg/day 
(1-2). During aplasia, the patient developed fatal septic shock with 
Pseudomonas aeruginosa etiology and SIRS (Systemic Inflammatory 
Response Syndrome) and died in September 2016. 
Discussion
Acute myeloid leukemia (AML) with the pericentric inversion 
of chromosome 16 [inv(16)(p13.1q22)] is recognized by the World 
Health Organization classification as unique entities within the 
category “AML with recurrent genetic abnormalities [1,2]. Among 
adults with de novo AML, inv(16) is in 5-8% of the patients [3]. 
Both the t(8;21) and inv(16) aberration result in formation of novel 
chimeric fusions involving genes of the core-binding factor (CBF) 
complex, a master regulator of definitive hematopoiesis providing 
the common designation CBF-AML [4,5]. Compared with other 
cytogenetic AML groups, patients with CBF-AML are considered 
a favorable AML risk group based on their high remission rate and 
survival probabilities. However, approximately 50% of patients with 
CBF-AML are not cured. Full-length RUNX1-RUNX1T1 and CBFB-
MYH11 fusions are considered as preleukemic conditions in CBF 
leukemogenesis, but they alone are not sufficient to induce leukemic 
transformation. The acquisition of additional genetic hits is necessary 
for the development of a leukemic phenotype [4,5]. More than 90% 
of AML with inv(16) harbor additional secondary mutations affecting 
c-KIT, FLT3, NRAS, and KRAS [6]. I was found that c-KIT mutation 
adversely affected the relapse rate [7,8]. According to the current 
NCCN guidelines, AML with t(8;21) or inv(16) and mutated KIT are 
considered as intermediate-risk AML, not favorable-risk AML [9]. 
AlloHSCT is increasingly used as a potentially curative treatment 
for acute myeloid leukemia (AML). However, relapse remains an 
important cause of treatment failure with relapse rates ranging from 
30% to 70% [10-12]. Extramedullary relapses are known to occur, 
either as isolated sites or in combination with marrow relapse [13-
17]. The incidence of leukemia extramedullary relapse (EMR) is 
difficult to determine. Based on retrospective data presented in the 
published case series and small sample studies, it is estimated at 
5-12% [15,18-23]. A literature review of 112 published cases of AML 
extramedullary relapse finds a median onset time of 17 months 
(range 1-121) post-transplant, with sites reported (in order of highest 
frequency) in skin, breast, bone, testis, serosa, gynecological tract, and 
bladder [15]. The potential mechanism of the development of EMR 
without coexisting leukemic marrow involvement is that the graft-
versus-leukemia (GVL) effect is more potent in the marrow and may 
be weaker in the extramedullary sites. Donor lymphocyte infusion 
(DLI), which may augment, potentiate the GVL effect and finally 
eradicate marrow remnants of leukemic cells and at the same time 
might not be as effective in extramedullary leukemic tumor cells [24]. 
GVL effect derived from chronic graft versus host disease (GVHD) 
prevents marrow relapse and does not prevent EMR. Furthermore, 
previous extensive chronic GVHD has been frequently observed 
in patients developing EMR [25]. EMR following alloHSCT has a 
dismal prognosis and management in the post-transplant setting is 
extremely difficult [17,18]. Systemic chemotherapy, in addition to 
EMR involved areas localized irradiation, has been administered to 
prevent overt leukemia recurrence. However, patients who develop 
EMR have been previously treated with high-dose chemotherapy, 
radiotherapy, GVHD related immunosuppression and their risk of 
further treatment toxicity is very high [17].
The prognostic significance of c-KIT mutations in CBF AML is 
important not only for outcome prediction, but also for therapeutic 
implications. It has been shown that, like other mutations of tyrosine 
kinase (TK) genes in leukemia - BCR-ABL and FLT3 internal tandem 
duplication, gain-of-function KIT mutations may also serve as a target 
for TK inhibitors. The case, described above, was unusual presentation 
of late extramedullary CBF-leukemia relapse after alloHSCT with 
concomitant left ovary and left side large intestine infiltration of 
surrounding structures, spreading locally. Both molecular MRD and 
PET/CT imaging were sensitive EMR diagnostic tools. The patient 
was treated with surgery and chemotherapy but also with new 
strategies: TK inhibitor with hypomethylating agent to reduce disease 
burden with effective regression. Systemic chemotherapy, improves 
treatment efficacy. However, possibility of severe complications 
in patients with EMR after alloHSCT is extremely high. In parallel 
Figure 1: Extramedullary leukemia relapse PET/CT images MIP (A) and fusion (B) indicate multiple sites of FDG uptake, including descending colon, the border 
of descending colon and distal segment and intestinal loops, right from the rectum.
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with EMR, presence of active GVHD in majority of patients creates 
unique immunological conditions, that predispose these patients to 
the development of both-subsequent EMR in diverse localizations 
and life-threatening complications related to chemotherapy.
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